Related Experiment Video
Updated: Mar 19, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Do platinum salts fit all triple negative breast cancers?
L Gerratana1, V Fanotto1, G Pelizzari1
1Department of Medical and Biological Sciences, University of Udine, Udine, Italy; Department of Medical Oncology, University Hospital of Udine, Udine, Italy.
Abstract:
Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and poor prognosis once metastatic. Pre-clinical and clinical data suggest that TNBC could be more sensitive to platinum-based chemotherapy, especially among BRCA1/2-mutated patients. In recent years, several randomised trials have been conducted to evaluate platinum efficacy in both early-stage and advanced TNBC, with conflicting results especially for long-term outcomes. Experimental studies are now focusing on identifying biomarkers of response to help selecting patients who may benefit most from platinum-based therapies, including BRCA1/2 mutational status and genomic instability signatures (such as HRD-LOH or HRD-LST scores). A standard therapy for TNBC is still missing and platinum-based regimens represent an emerging therapeutic option for selected patients with a defect in the homologous recombination repair system. The identification of these patients through validated biomarker assays will be crucial to optimize the use of currently approved agents in TNBC.
Insights
Triple-negative breast cancer (TNBC) may respond to platinum chemotherapy, particularly in patients with BRCA1/2 mutations. Identifying biomarkers like homologous recombination deficiency (HRD) is key to selecting patients for this emerging treatment.
Area of Science:
- Oncology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) is aggressive with limited treatment options.
- Platinum-based chemotherapy shows potential, especially in BRCA1/2-mutated TNBC.
- Randomized trials on platinum efficacy in TNBC have yielded conflicting long-term results.
Purpose of the Study:
- To evaluate the efficacy of platinum-based chemotherapy in TNBC.
- To identify biomarkers for predicting response to platinum therapy.
- To optimize treatment selection for TNBC patients.
Main Methods:
- Review of pre-clinical and clinical data on platinum-based chemotherapy in TNBC.
- Analysis of randomized trials assessing platinum efficacy.
- Focus on biomarkers including BRCA1/2 mutational status and genomic instability signatures (HRD-LOH, HRD-LST).
Main Results:
- Conflicting results exist regarding long-term outcomes of platinum-based chemotherapy in TNBC.
- Biomarkers such as BRCA1/2 mutations and HRD signatures are under investigation for patient selection.
- Platinum regimens are an emerging option for selected TNBC patients with homologous recombination repair defects.
Conclusions:
- A definitive standard therapy for TNBC is lacking.
- Identifying patients with homologous recombination repair defects via validated biomarker assays is crucial.
- Optimizing the use of approved platinum agents in TNBC depends on accurate patient selection.
More Related Videos
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...